Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study.
Alessandro RizzoVeronica MollicaAndrea MarchettiGiacomo NuvolaMatteo RoselliniElisa TassinariJavier Molina-CerrilloZin W MyintTomas BuchlerFernando Sabino Marques MonteiroEnrique GrandeMatteo SantoniFrancesco MassariPublished in: Cancers (2022)
Adjuvant anti-PD-1/PD-L1 treatment is associated with an increased RFS in the overall population and in subgroups divided according to age and gender.